157 related articles for article (PubMed ID: 21273345)
1. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Horgan AM; Bradbury PA; Amir E; Ng R; Douillard JY; Kim ES; Shepherd FA; Leighl NB
Ann Oncol; 2011 Aug; 22(8):1805-11. PubMed ID: 21273345
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
[TBL] [Abstract][Full Text] [Related]
3. Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Cufer T; Vrdoljak E; Gaafar R; Erensoy I; Pemberton K;
Anticancer Drugs; 2006 Apr; 17(4):401-9. PubMed ID: 16549997
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Sun Y; Wu YL; Li LY; Liao ML; Jiang GL; Kim ES; Douillard JY; Milenkova T
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):377-80. PubMed ID: 21875470
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Kim ES; Hirsh V; Mok T; Socinski MA; Gervais R; Wu YL; Li LY; Watkins CL; Sellers MV; Lowe ES; Sun Y; Liao ML; Osterlind K; Reck M; Armour AA; Shepherd FA; Lippman SM; Douillard JY
Lancet; 2008 Nov; 372(9652):1809-18. PubMed ID: 19027483
[TBL] [Abstract][Full Text] [Related]
6. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
[TBL] [Abstract][Full Text] [Related]
7. The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Ganguli A; Wiegand P; Gao X; Carter JA; Botteman MF; Ray S
Qual Life Res; 2013 Jun; 22(5):1015-26. PubMed ID: 22806607
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
Lewis G; Peake M; Aultman R; Gyldmark M; Morlotti L; Creeden J; de la Orden M
J Int Med Res; 2010; 38(1):9-21. PubMed ID: 20233509
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Thongprasert S; Tinmanee S; Permsuwan U
Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
[TBL] [Abstract][Full Text] [Related]
10. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Douillard JY; Shepherd FA; Hirsh V; Mok T; Socinski MA; Gervais R; Liao ML; Bischoff H; Reck M; Sellers MV; Watkins CL; Speake G; Armour AA; Kim ES
J Clin Oncol; 2010 Feb; 28(5):744-52. PubMed ID: 20038723
[TBL] [Abstract][Full Text] [Related]
11. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Maruyama R; Nishiwaki Y; Tamura T; Yamamoto N; Tsuboi M; Nakagawa K; Shinkai T; Negoro S; Imamura F; Eguchi K; Takeda K; Inoue A; Tomii K; Harada M; Masuda N; Jiang H; Itoh Y; Ichinose Y; Saijo N; Fukuoka M
J Clin Oncol; 2008 Sep; 26(26):4244-52. PubMed ID: 18779611
[TBL] [Abstract][Full Text] [Related]
12. The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
Zhao YL; Han S; Pu R; Shi LW
Indian J Cancer; 2014 Mar; 51 Suppl 3():e86-91. PubMed ID: 25818741
[TBL] [Abstract][Full Text] [Related]
13. Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
Zhu J; Li T; Wang X; Ye M; Cai J; Xu Y; Wu B
BMC Cancer; 2013 Jan; 13():39. PubMed ID: 23360224
[TBL] [Abstract][Full Text] [Related]
14. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Melosky B; Peacock S
J Thorac Oncol; 2011 Dec; 6(12):2097-103. PubMed ID: 22052223
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
[TBL] [Abstract][Full Text] [Related]
16. Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.
Sekine I; Ichinose Y; Nishiwaki Y; Yamamoto N; Tsuboi M; Nakagawa K; Shinkai T; Negoro S; Imamura F; Eguchi K; Takeda K; Itoh Y; Tamura T; Saijo N; Fukuoka M
Ann Oncol; 2009 Sep; 20(9):1483-1488. PubMed ID: 19282468
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
18. A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Manegold C; Gatzemeier U; Buchholz E; Smith RP; Fandi A
Clin Lung Cancer; 2005 May; 6(6):343-9. PubMed ID: 15943894
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer.
Holmes J; Dunlop D; Hemmett L; Sharplin P; Bose U
Pharmacoeconomics; 2004; 22(9):581-9. PubMed ID: 15209527
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
